Keyphrases
Placebo
100%
Type 2 Diabetes Mellitus (T2DM)
100%
Exenatide
100%
Cardiovascular Outcomes
100%
Exenatide Once Weekly
100%
Once-weekly
66%
Cardiovascular Disease
50%
Type 2 Diabetic Patients
50%
Composite Outcome
33%
Nonfatal Myocardial Infarction
33%
Nonfatal Stroke
33%
Hazard Ratio
16%
Intention-to-treat Analysis
16%
Acute Coronary Syndrome
16%
Confidence Interval
16%
Placebo Groups
16%
Serious Adverse Events
16%
Pancreatic Cancer
16%
Hospitalization
16%
Non-inferiority
16%
Major Adverse Cardiovascular Events
16%
Acute Pancreatitis
16%
Extended Release
16%
Subcutaneous Injection
16%
Death Rate
16%
Heart Failure Hospitalization
16%
Usual Care
16%
First Occurrence
16%
Cardiovascular Effects
16%
Fatal Stroke
16%
Medullary Thyroid Carcinoma
16%
Pharmacology, Toxicology and Pharmaceutical Science
Exendin 4
100%
Placebo
100%
Non Insulin Dependent Diabetes Mellitus
100%
Cardiovascular Disease
57%
Heart Infarction
28%
Cerebrovascular Accident
28%
Adverse Event
14%
Acute Coronary Syndrome
14%
Congestive Heart Failure
14%
Pancreas Cancer
14%
Subcutaneous Injection
14%
Acute Pancreatitis
14%
Thyroid Medullary Carcinoma
14%